Royal Marsden Nhs Foundation Trust

This study tested adding the immune-boosting drug pembrolizumab to standard chemoradiation for people with advanced cervical cancer. The goal was to see if the combination is safe and to find the best dose. Only one person was enrolled before the study was stopped early, so resul…

This phase II trial tested whether adding radiotherapy to the immunotherapy drug pembrolizumab could better control advanced melanoma than pembrolizumab alone. Only 17 people took part before the study was stopped early. The goal was to see if radiation could trigger an 'abscopal…

This early-phase trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemoradiation is safe for people with stage IV head and neck cancer. Only 3 patients were enrolled before the study was stopped. The main goal was to find the highest safe do…

This early-phase trial tested the drug pembrolizumab (Keytruda) combined with targeted radiation (SBRT) in 5 people with advanced malignant pleural mesothelioma, a rare cancer of the lung lining. The goal was to check safety and find the right dose. The study was terminated early…

This early-phase trial tested the combination of the immunotherapy drug pembrolizumab (Keytruda) with precise, high-dose radiation (SBRT) in patients with advanced non-small cell lung cancer that had progressed after chemotherapy. The study aimed to find the safest radiation dose…